Checchi Capital Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $285K | Sell |
457
-138
| -23% | -$93.9K | 0.01% | 494 |
|
|
2026
Q1 | $460K | Buy |
595
+111
| +23% | +$85K | 0.02% | 372 |
|
|
2025
Q4 | $374K | Hold |
484
| – | – | 0.02% | 385 |
|
|
2025
Q3 | $272K | Sell |
484
-248
| -34% | -$140K | 0.01% | 467 |
|
|
2025
Q2 | $384K | Buy |
732
+50
| +7% | +$27.9K | 0.02% | 397 |
|
|
2025
Q1 | $433K | Buy |
682
+9
| +1% | +$6.19K | 0.02% | 365 |
|
|
2024
Q4 | $479K | Sell |
673
-19
| -3% | -$15.9K | 0.03% | 334 |
|
|
2024
Q3 | $727K | Sell |
692
-1
| -0.1% | -$1.11K | 0.04% | 251 |
|
|
2024
Q2 | $728K | Buy |
693
+3
| +0.4% | +$2.91K | 0.04% | 244 |
|
|
2024
Q1 | $664K | Buy |
690
+23
| +3% | +$21.9K | 0.05% | 265 |
|
|
2023
Q4 | $586K | Buy |
667
+46
| +7% | +$37.9K | 0.05% | 277 |
|
|
2023
Q3 | $511K | Sell |
621
-36
| -5% | -$28.3K | 0.05% | 283 |
|
|
2023
Q2 | $472K | Buy |
657
+8
| +1% | +$6.17K | 0.04% | 303 |
|
|
2023
Q1 | $533K | Buy |
649
+19
| +3% | +$14.3K | 0.05% | 276 |
|
|
2022
Q4 | $455K | Sell |
630
-99
| -14% | -$73K | 0.05% | 295 |
|
|
2022
Q3 | $502K | Buy |
729
+12
| +2% | +$7.55K | 0.05% | 268 |
|
|
2022
Q2 | $417K | Buy |
717
+118
| +20% | +$76.7K | 0.04% | 328 |
|
|
2022
Q1 | $418K | Buy |
599
+69
| +13% | +$43.7K | 0.04% | 314 |
|
|
2021
Q4 | $335K | Buy |
530
+4
| +0.8% | +$2.46K | 0.03% | 365 |
|
|
2021
Q3 | $318K | Buy |
526
+23
| +5% | +$14.3K | 0.03% | 350 |
|
|
2021
Q2 | $281K | Sell |
503
-85
| -14% | -$43.1K | 0.03% | 398 |
|
|
2021
Q1 | $278K | Sell |
588
-74
| -11% | -$36K | 0.03% | 394 |
|
|
2020
Q4 | $320K | Sell |
662
-49
| -7% | -$26.4K | 0.03% | 322 |
|
|
2020
Q3 | $398K | Buy |
711
+5
| +0.7% | +$3.03K | 0.04% | 243 |
|
|
2020
Q2 | $440K | Buy |
706
+79
| +13% | +$44.8K | 0.05% | 222 |
|
|
2020
Q1 | $306K | Sell |
627
-25
| -4% | -$10.3K | 0.03% | 248 |
|
|
2019
Q4 | $245K | Buy |
+652
| New | +$219K | 0.03% | 357 |
|
|
2019
Q2 | – | Sell |
-487
| Closed | -$200K | – | 442 |
|
|
2019
Q1 | $200K | Buy |
+487
| New | +$201K | 0.02% | 393 |
|
|
2018
Q4 | – | Sell |
-689
| Closed | -$278K | – | 431 |
|
|
2018
Q3 | $278K | Buy |
689
+22
| +3% | +$8.37K | 0.03% | 335 |
|
|
2018
Q2 | $230K | Buy |
667
+38
| +6% | +$11.9K | 0.03% | 352 |
|
|
2018
Q1 | $217K | Sell |
629
-12
| -2% | -$4.17K | 0.03% | 366 |
|
|
2017
Q4 | $241K | Buy |
641
+101
| +19% | +$40.9K | 0.03% | 350 |
|
|
2017
Q3 | $241K | Sell |
540
-22
| -4% | -$10.5K | 0.02% | 330 |
|
|
2017
Q2 | $276K | Sell |
562
-64
| -10% | -$28K | 0.03% | 293 |
|
|
2017
Q1 | $243K | Buy |
626
+29
| +5% | +$10.7K | 0.03% | 333 |
|
|
2016
Q4 | $219K | Sell |
597
-42
| -7% | -$16K | 0.03% | 333 |
|
|
2016
Q3 | $257K | Buy |
639
+53
| +9% | +$21.3K | 0.03% | 299 |
|
|
2016
Q2 | $205K | Sell |
586
-21
| -3% | -$8.09K | 0.02% | 338 |
|
|
2016
Q1 | $219K | Sell |
607
-120
| -17% | -$49.4K | 0.05% | 313 |
|
|
2015
Q4 | $395K | Buy |
727
+193
| +36% | +$105K | 0.1% | 180 |
|
|
2015
Q3 | $248K | Buy |
534
+9
| +2% | +$4.83K | 0.07% | 262 |
|
|
2015
Q2 | $268K | Sell |
525
-26
| -5% | -$12.7K | 0.07% | 257 |
|
|
2015
Q1 | $249K | Buy |
551
+36
| +7% | +$15.3K | 0.07% | 268 |
|
|
2014
Q4 | $211K | Buy |
+515
| New | +$203K | 0.08% | 281 |
|
Other funds holding REGN
Checchi Capital Advisers's REGN Position: Q2 2026 in Review
Checchi Capital Advisers reduced its Regeneron Pharmaceuticals (REGN) stake by 23% in Q2 2026, selling an estimated $93.9K and leaving 457 shares worth $285K. The position accounts for 0.01% of the portfolio, ranked #494.
Checchi Capital Advisers first reported a position in REGN in Q4 2014 and has held it in 44 quarters since. The position peaked at $728K in Q2 2024. 729 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Checchi Capital Advisers held 457 shares of Regeneron Pharmaceuticals worth $285K as of Q2 2026.
- Checchi Capital Advisers sold 138 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $93.9K.
- Regeneron Pharmaceuticals made up 0.01% of Checchi Capital Advisers's portfolio in Q2 2026, its #494 holding.
- Checchi Capital Advisers first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 44 quarters since.
- Checchi Capital Advisers's Regeneron Pharmaceuticals position peaked at $728K in Q2 2024.
- 729 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Checchi Capital Advisers's 13F filing for Q2 2026, filed 4 Aug 2026.